Uterine Cancer Symptoms, Stages, Diagnosis and Treatment
In this article
What Is Uterine (Endometrial) Cancer?
Uterine cancer (medically called endometrial cancer) is the most common cancer of the female reproductive system and stands out for two important features: its worldwide incidence is steadily rising — largely in parallel with increasing obesity rates — and its treatment approach has been almost completely rewritten in recent years. The molecular classification system described in 2013 is now a clinical tool that directly determines how much treatment each patient receives, rather than merely an academic curiosity; and two different immunotherapy+chemotherapy combinations approved on the same day, July 31, 2024, changed the decades-old treatment paradigm in advanced disease. This guide comprehensively covers everything from the disease's anatomy and staging to molecular classification and current systemic treatment options (including 2026).
Anatomy of the Uterus (Womb)
The uterus (womb) is a hollow, pear-shaped organ where the fetus completes its development; it lies between the bowel (sigmoid colon) and urinary bladder and is approximately 7,5 cm long. Its lower part ends in the cervix, which connects to the vagina. The uterus consists of three layers: the functional inner layer where the menstrual cycle occurs and which has placenta-related functions in pregnancy, the endometrium; the muscle layer of the uterus, the myometrium; and the peritoneal layer covering the outer surface of the uterus, the perimetrium. The vast majority of uterine cancers develop from the endometrial layer — therefore, "uterine cancer" and "endometrial cancer" are used synonymously in everyday usage, and this guide primarily addresses endometrial cancer.
How Common Is It? (Current Statistics)
According to the International Agency for Research on Cancer's (IARC) "Global cancer statistics 2024" report (Sung H, et al., CA: A Cancer Journal for Clinicians, 2026, DOI: 10.3322/caac.70090), worldwide data for 2024 reported approximately 420.242 new uterine (endometrial) cancer cases and 99.976 deaths due to this disease . Uterine cancer is the most common female reproductive system cancer, with %52,9 of cases in Asia and %26,7 in Europe; the highest incidence is reported in North America and Northern/Western European countries.
According to the American Cancer Society's "Cancer Statistics, 2026" report (Siegel RL, et al., CA: A Cancer Journal for Clinicians, 2026, DOI: 10.3322/caac.70043), the USA is expected to have approximately, in 2026, 69.680 new uterine cancer cases and 13.630 deaths . Unlike most other cancer types, uterine cancer incidence has for many years been increasing — an increase thought to be largely associated with rising obesity prevalence (fat tissue stimulates the endometrium by contributing to estrogen production). Even more concerning is the faster increase in mortality rates than incidence — suggesting a disproportionate increase in aggressive, less common subtypes (such as the serous/clear cell types discussed below). The median age at diagnosis is generally in the 60s; approximately %75 of patients are diagnosed over age 50 and during menopause.
As worldwide, uterine cancer is among the most common female reproductive system cancers in Türkiye. Because symptoms such as vaginal bleeding arise early, the vast majority of patients in Türkiye, as worldwide, are diagnosed at an early stage, generally associated with a good prognosis — however, the small number of aggressive subtypes discussed below require a more careful approach regardless of stage.
Risk Factors
- Obesity (BMI ≥30) — the strongest modifiable risk factor
- Prolonged exposure to unopposed estrogen (without progesterone)
- Never having given birth
- Early onset of menstruation / late menopause
- Polycystic ovary syndrome (PCOS)
- Type 2 diabetes
- Tamoxifen use (in breast cancer treatment)
- Family history of uterine, ovarian or colorectal cancer (suspected Lynch syndrome)
Symptoms
The most important advantage of uterine cancer is that approximately %90 of patients have a symptom that can be noticed early — enabling %75 of cases to be diagnosed at an early stage and 5-year survival to be around %90.
- Abnormal vaginal bleeding — bleeding between periods, postmenopausal bleeding or unusually heavy menstrual bleeding (the most common and important symptom)
- Abnormal vaginal discharge (may be blood-free discharge in approximately %10 of cases)
- Pelvic pain or a sensation of a mass (usually in more advanced stages)
- Unexplained weight loss (usually in more advanced stages)
Any vaginal bleeding or spotting in a woman who has entered menopause — however small the amount — must be assessed by a gynecologist. This symptom can sometimes have noncancerous causes, but should never be ignored because it is the earliest and most reliable warning sign of uterine cancer.
Genetics: Lynch Syndrome
Approximately %3-5 of uterine cancer cases are associated with an inherited DNA mismatch repair (MMR) gene mutation causing Lynch syndrome . Women carrying Lynch syndrome have a lifetime uterine cancer risk up to 10 times that of the general population — this risk may be even more pronounced than the colorectal cancer risk associated with the same syndrome. Although there is no uterine cancer screening program for the general population, annual gynecological examination is recommended for Lynch syndrome carriers or those with a family history of Lynch syndrome. Screening for Lynch syndrome by MMR immunohistochemistry or MSI testing on tumor tissue is now a universal standard for every newly diagnosed uterine cancer patient (discussed in detail in the molecular classification section below).
Histological Classification: Type I and Type II
Traditionally, uterine cancer is divided into two broad categories — although still taught, the molecular classification described below now offers a more precise, treatment-guiding approach.
| Type | Features |
|---|---|
| Type I (Endometrioid, ~%80-85) | Estrogen-dependent, generally low-grade (grade 1-2), with a good prognosis; strongly associated with obesity/unopposed estrogen |
| Type II (Serous, clear cell and carcinosarcoma, ~%10-15) | Estrogen-independent, generally high-grade, with aggressive behavior; this group accounts for a disproportionately large share of deaths; approximately %30 of serous carcinomas have HER2 overexpression (discussed below) |
How Is It Diagnosed?
The first step in assessing abnormal vaginal bleeding is measuring endometrial thickness with transvaginal ultrasonography. Definitive diagnosis requires tissue sampling by an office-based endometrial biopsy or, when necessary, hysteroscopy-guided dilation and curettage (D&C) .
Molecular Classification: The Development That Rewrote Treatment
A groundbreaking study published in 2013 as part of The Cancer Genome Atlas (TCGA) project (Nature, 2013, DOI: 10.1038/nature12113) demonstrated that, independently of morphological appearance, uterine cancer is divided into 4 distinct molecular subgroups . This complex genomic classification entered clinical practice through a simplified surrogate test developed in 2015 and usable in routine pathology laboratories, ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer). The updated ESGO/ESTRO/ESP guideline published in 2023 now recommends that this molecular classification be performed routinely in all uterine cancer patients and directly shapes adjuvant treatment decisions accordingly — the most fundamental change in the field over the past decade.
| Molecular Subgroup | Approximate Proportion | Prognosis |
|---|---|---|
| POLE-ultramutated | ~%7-10 | Excellent — in most cases, even with other high-risk features, adjuvant treatment intensity can be reduced (de-escalation) |
| MMR-deficient (dMMR) / MSI-H | ~%25-30 | Intermediate; potential for an exceptional response to immunotherapy (discussed below); frequently associated with Lynch syndrome |
| NSMP (No Specific Molecular Profile) | ~%40-50 | Intermediate; assessed together with hormone receptor status and other conventional factors |
| p53 Abnormal (p53abn) | ~%10-15 | Worst — the most aggressive behavior and highest recurrence risk regardless of histological type (including endometrioid-appearing tumors); adjuvant treatment is generally intensified |
A striking example of the clinical importance of molecular classification: an endometrioid tumor appearing low-grade and benign under the microscope is actually considered high-risk if it belongs to the p53abn subgroup and may require intensive adjuvant treatment — conversely, a high-grade-appearing tumor that is POLE-ultramutated may have an excellent prognosis, allowing unnecessary intensive treatment to be avoided. This clearly shows why the former risk classification based only on microscopic appearance (histology/grade) was inadequate.
Staging: The FIGO/TNM System
The FIGO (International Federation of Gynecology and Obstetrics) and AJCC TNM systems used in uterine cancer staging are based on essentially the same principles: local tumor spread (T), lymph node involvement (N) and distant metastasis (M).
Cancer cells are only in the surface layer of the endometrium and have not progressed into underlying layers. Surgery alone is usually sufficient at this stage.
IA: Cancer is in the endometrium or has spread to less than half the myometrium. IB: Cancer has spread to more than half the myometrium but has not extended outside the uterine body. Neither substage has lymph node or distant spread.
Cancer has progressed from the uterine body to the supporting connective tissue (stroma) of the cervix; there is no spread outside the uterus, to lymph nodes or to distant sites.
IIIA: Cancer has spread to the outer surface of the uterus (serosa) and/or fallopian tubes/ovaries. IIIB: Cancer has spread to the vagina or tissues around the uterus (parametrium). Neither substage has lymph node or distant spread.
IIIC1: Cancer has spread to pelvic lymph nodes, but not to para-aortic lymph nodes or distant sites. IIIC2: Cancer has spread to para-aortic (around the aorta) lymph nodes, but not to distant sites.
IVA: Cancer has spread to the inner layer (mucosa) of the bladder or rectum.
IVB: Cancer has spread to distant lymph nodes, the upper abdomen, the omentum or distant organs such as the lungs/bones.
Surgical Treatment
Approximately %90-95 of patients are suitable for surgery at diagnosis, and surgery is the first step in treatment. Standard surgery includes removal of the uterus with both ovaries and fallopian tubes (total hysterectomy + bilateral salpingo-oophorectomy) and lymph node assessment.
The former standard was complete removal of all pelvic/para-aortic lymph nodes (lymphadenectomy) — but this could cause permanent side effects such as lymphedema. The current approach, based on FIRES findings, involves injecting a dye or fluorescent marker during surgery to identify the first lymph node reached by the tumor's lymphatic drainage (sentinel lymph node) and removing only that node/those nodes. This method provides similar diagnostic accuracy to complete lymphadenectomy in low- and intermediate-risk patients while significantly reducing lymphedema risk, and is widely adopted in NCCN guidelines. Today, operations are largely performed using minimally invasive (laparoscopic or robotic) techniques, accelerating recovery.
For young patients wishing to preserve fertility who have early-stage (confined to the uterus), low-grade (grade 1) endometrioid cancer, a fertility-preserving approach may be considered instead of surgery using progestin-based hormonal treatment (high-dose oral progestin or a levonorgestrel-releasing intrauterine device). This approach requires close histological monitoring and should only be considered in carefully selected patients managed by an experienced gynecological oncology team; standard surgical treatment is generally recommended after childbearing is completed.
Postoperative Risk Classification: The ESGO/ESTRO/ESP System and Percentage-Based Risk Strata
Postoperative pathology results (stage, grade, lymphovascular invasion, histological type) are now assessed with the molecular subgroup information described above. The ESGO/ESTRO/ESP guideline updated in 2023 replaced the former "low/intermediate/high" three-part classification with a percentage-based risk stratification system based on 5-year recurrence probability — meaning that adjuvant treatment decisions now rely on a measurable probability calculation rather than an estimate:
| Risk Stratum | Approximate 5-Year Recurrence Probability | Typical Profile |
|---|---|---|
| Low risk | <%8 | Stage I, grade 1-2 endometrioid, myometrial invasion <%50, no lymphovascular invasion |
| Intermediate risk | %8-14 | Stage I, grade 1-2 endometrioid, myometrial invasion ≥%50; or grade 3 endometrioid, invasion <%50 |
| High-intermediate risk | %15-24 | Disease with substantial lymphovascular invasion; or Stage IB grade 3 endometrioid; or Stage II |
| High risk | ≥%25 | Stage III-IVA without residual disease, serous/clear cell/carcinosarcoma histology, p53abn subgroup (if myometrial invasion is present) |
| Uncertain risk | Variable | Molecular subgroup unknown or unclassifiable; decisions use conventional histopathological criteria |
The most important innovation in this system is that molecular findings can move the conventional histopathological risk stratum up or down: POLE-ultramutated tumors, even with all other high-risk features (grade 3, deep invasion, lymphovascular invasion), up to Stage II are automatically downgraded to low risk — because recurrence risk in this subgroup is close to zero, and clinical studies have shown that adjuvant treatment does not benefit these patients. Conversely, p53abn tumors — however benign their histological appearance — from Stage IA2/IA3 (with myometrial invasion) onward are automatically upgraded to high risk because this subgroup may behave aggressively. These rules show that the mismatch between microscopic appearance and actual biological behavior described in "Why Is It So Important? An Example" has now become a concrete treatment rule in official guidelines.
Adjuvant Treatment Decisions: Guided by PORTEC and GOG Studies
The choice of adjuvant treatment (none, vaginal brachytherapy, external radiotherapy, chemotherapy or combinations) according to the risk strata above has been established through decades of successive large randomized trials (the PORTEC series and GOG studies). Each answered the question left by the previous study, gradually refining treatment:
PORTEC-1 (Creutzberg CL, et al., Lancet, 2000) showed that postoperative external radiotherapy significantly reduced locoregional recurrence in intermediate-risk early-stage patients compared with observation alone (approximately %4-5 in the radiotherapy group versus around %14 with observation) — but no significant overall survival difference was found, because most patients with recurrence could be successfully managed with salvage treatment. This led to questioning which subgroups would actually benefit, rather than giving radiotherapy "routinely to every intermediate-risk patient."
PORTEC-2 (Nout RA, et al., Lancet, 2010; 10-year long-term follow-up: Wortman BG, et al., Br J Cancer, 2018) showed that in high-intermediate-risk patients, vaginal brachytherapy was non-inferior (equivalent) to external radiotherapy in preventing local recurrence, but gastrointestinal side effects and the negative impact on quality of life were far lower. This study is the key evidence that made vaginal brachytherapy the preferred standard over external radiotherapy in high-intermediate-risk disease today.
PORTEC-3 (de Boer SM, et al., Lancet Oncol, 2018 and 2019 update) compared the addition of concurrent and sequential chemotherapy to radiotherapy (chemoradiotherapy) with radiotherapy alone in high-risk patients (including Stage III and serous/clear cell histology). Result: 5-year overall survival was %81,4 with chemoradiotherapy versus %76,1 with radiotherapy alone (HR 0,70) — the difference was particularly most pronounced in Stage III disease and serous histology ; in Stage I-II patients, the benefit of additional chemotherapy was much more limited. This result again highlighted the importance of distinguishing "who actually benefits from chemotherapy."
The molecular subgroup analysis of PORTEC-3 published in 2020 (León-Castillo A, et al., J Clin Oncol, 2020) revealed that the original study result did not apply to all patients, but largely arose from patients in the p53abn subgroup : adding chemoradiotherapy significantly reduced recurrence and death risk in this subgroup, whereas patients in the POLE-ultramutated subgroup already had excellent outcomes regardless of treatment received (radiotherapy alone or chemoradiotherapy) — thus, additional chemotherapy only added a risk of side effects without providing benefit. This analysis is the direct evidence base for the molecular de-escalation/escalation rules described in "Postoperative Risk Classification."
GOG-258/NRG258 (Matei D, et al., N Engl J Med, 2019; long-term follow-up data published in 2024-2025) investigated whether chemoradiotherapy or 6 cycles of chemotherapy alone (carboplatin+paclitaxel) was superior in advanced-stage patients with Stage III-IVA or serous histology. The result was an initially unexpected balance: locoregional recurrence was significantly lower with chemoradiotherapy, but distant (organ) recurrence was lower with chemotherapy alone — these opposing effects balanced each other, with no significant difference in progression-free or overall survival between groups on long-term follow-up. The practical result: systemic chemotherapy alone has become a reasonable option in advanced-stage patients (particularly extensive disease with a high systemic recurrence risk), but adding radiotherapy may still be preferred when locoregional control is a priority (for example, substantial vaginal/parametrial involvement) — the decision is individualized to the patient's recurrence pattern.
Carcinosarcoma: An Aggressive Subtype Requiring Separate Consideration
Carcinosarcoma (formerly malignant mixed Müllerian tumor) is a rare but extremely aggressive subtype within the Type II group that requires separate clinical consideration because it contains both epithelial (carcinoma) and mesenchymal (sarcoma) components.
Historically, ifosfamide-based chemotherapy regimens (ifosfamide+paclitaxel) were used in carcinosarcoma. GOG-261 (Powell MA, et al., J Clin Oncol, 2022) compared carboplatin+paclitaxel with ifosfamide+paclitaxel and showed that carboplatin+paclitaxel was non-inferior (equivalent) and even gave slightly better numerical results: median overall survival was 37 months with carboplatin+paclitaxel versus 29 months with ifosfamide+paclitaxel (HR 0,87), and progression-free survival was 16 versus 12 months (HR 0,735) — moreover, carboplatin+paclitaxel was significantly less toxic and easier to administer. These results made carboplatin+paclitaxel the preferred standard regimen in carcinosarcoma as well (as in other Type II tumors); ifosfamide-based regimens are now considered only in selected refractory cases.
Radiotherapy: Delivery Methods and Side Effects
Radiotherapy works by damaging cancer cell DNA with high-energy X-rays and is given after surgery in uterine cancer to prevent recurrence. Based on the evidence detailed above in the PORTEC studies, there are two main delivery methods: external (external beam) radiotherapy (delivered from outside the body once daily, 5 days a week for a total of 5-6 weeks) and vaginal brachytherapy (radiation delivered directly to the vagina/cancerous area through a catheter minimizes effects on surrounding healthy tissues; the preferred method in high-intermediate-risk disease after PORTEC-2).
Short-term radiotherapy side effects include fatigue, urinary frequency, burning during urination and bowel complaints; these symptoms generally subside a few months after treatment ends. Rare long-term effects include urinary/fecal incontinence and vaginal dryness and narrowing — these long-term effects are significantly less common with vaginal brachytherapy than external radiotherapy.
Systemic Chemotherapy
As adjuvant chemotherapy in high-risk early-stage disease and first-line systemic treatment in advanced-stage (Stage III-IV) or metastatic/recurrent disease, the carboplatin + paclitaxel combination (generally 6 cycles) has long been the standard treatment backbone. However, treatment added to this backbone has changed fundamentally in the past two years — discussed in detail below.
First-Line Immunotherapy: From GARNET to RUBY, a Gradual Approval History
The most important recent development in systemic uterine cancer treatment is moving immunotherapy in advanced/recurrent disease directly into first-line treatment instead of second-line . This development occurred gradually through four successive FDA decisions rather than a single approval.
Before RUBY, dostarlimab's first FDA approval in uterine cancer was actually for use alone (as monotherapy), only in the dMMR/MSI-H subgroup, in patients progressing after chemotherapy. Based on GARNET data, dostarlimab received accelerated FDA approval on April 22, 2021 in this narrow population, with a reported response rate (ORR) of %42,3 — the first concrete demonstration of this drug class's potential in uterine cancer, laying the groundwork for RUBY's design.
RUBY showed that adding dostarlimab to first-line carboplatin/paclitaxel chemotherapy followed by dostarlimab maintenance provided significant benefit over chemotherapy alone (Mirza MR, et al., N Engl J Med, 2023). The benefit was striking in the dMMR/MSI-H subgroup (2-year progression-free survival %61,4 versus %15,7); a more modest but significant benefit was also observed in pMMR/MSS (microsatellite stable). Approval proceeded in two stages: the combination was first approved on July 31, 2023 only for the dMMR/MSI-H subgroup, then, as benefit data for the entire population (including pMMR) became clear, on August 1, 2024 it was expanded to full approval regardless of microsatellite status (all-comers).
The competing NRG-GY018/KEYNOTE-868 study tested adding pembrolizumab to carboplatin/paclitaxel with an almost identical design, similarly showing a progression-free survival advantage in both dMMR and pMMR subgroups (Eskander RN, et al., N Engl J Med, 2023). This combination also received FDA approval close in time to RUBY's all-comer approval — as a result, patients and physicians now have multiple evidence-based first-line immunotherapy options.
Before these approvals, immunotherapy in advanced uterine cancer could be used only in patients progressing after chemotherapy (second-line). Now, the vast majority of eligible patients can access immunotherapy at the outset, when disease is most aggressive and treatment can make the greatest difference. Results in the dMMR/MSI-H subgroup in particular (approximately %25-30 of uterine cancers) show a magnitude of benefit rarely seen across oncology. The three-year process from GARNET to RUBY's all-comer approval also exemplifies how the FDA gradually progresses from a narrow accelerated approval to broad, evidence-based full approval.
Later-Line Treatment and the HER2-Targeted Approach
The pembrolizumab+lenvatinib combination is based on Study 309/KEYNOTE-775 data (Makker V, et al., N Engl J Med, 2022) and has long been an effective option in non-dMMR (pMMR) patients. Results by histological/molecular subgroup are as follows: In the pMMR subgroup , progression-free survival was 6,6 versus 3,8 months (HR 0,60), and overall survival 17,4 versus 12,0 months (HR 0,68); in the entire population (all-comers) , progression-free survival was 7,2 versus 3,8 months (HR 0,56), and overall survival 18,3 versus 11,4 months (HR 0,62) (comparison group: physician's choice of chemotherapy). The combination received full FDA approval on July 21, 2021 . As first-line immunotherapy+chemotherapy has now become standard, this combination is currently positioned more as a later-line option for patients progressing after first-line immunotherapy .
As noted above, approximately %30 of serous carcinomas show HER2 overexpression. The randomized phase 2 study by Fader AN and colleagues showed that, in advanced/recurrent HER2-positive serous carcinoma, chemotherapy benefited from the addition of trastuzumab : progression-free survival increased from 8,0 to 12,9 months (HR 0,46; P=0,005); updated overall survival analysis also reported significant benefit, from 24,4 to 29,6 months (HR 0,58; P=0,046). This approach is listed as a treatment option in NCCN guidelines — an interesting example of this "smart drug," used for decades in breast and stomach cancer, finding a new use in the most aggressive uterine cancer subtype.
DESTINY-PanTumor02 (J Clin Oncol, 2023) tested the antibody-drug conjugate trastuzumab deruxtecan across many tumor types (tumor-agnostically) according to HER2 expression. Results in the uterine cancer arm (n=40) were among the strongest in the entire study: the overall response rate was %57,5 in the whole cohort, reaching %84,6 in the HER2 IHC3+ subgroup; median progression-free survival was 11,1 months and median overall survival 26,0 months. Based on these striking results, trastuzumab deruxtecan received, on April 5, 2024 , tumor-agnostic accelerated FDA approval for all solid tumors expressing HER2 IHC3+ (including uterine cancer) — a very recent development offering a markedly more potent option than trastuzumab in HER2-positive uterine cancer.
Hormonal agents such as megestrol acetate or tamoxifen (%15-30 benefit rate) may be considered in selected patients with low-grade, hormone receptor-positive tumors who are unsuitable for chemotherapy. Although antiangiogenic agents such as bevacizumab and mTOR inhibitors (temsirolimus, everolimus) have been studied, they have not become part of routine standard treatment because strong phase 3 evidence is lacking.
Treatment Sequencing in Recurrent Disease: Decisions by Scenario
Treatment selection in recurrent uterine cancer depends on assessing multiple variables together rather than one algorithm: platinum sensitivity of the recurrence, molecular subgroup/MMR status, HER2 status, whether immunotherapy was received previously, and whether recurrence is local or distant. The scenarios below summarize the main decision points encountered in everyday clinical practice:
If recurrence is confined to the vagina or pelvis without previous radiotherapy, salvage radiotherapy (± brachytherapy) alone may provide long-term disease control, or even a permanent cure in some patients — therefore, this option must be assessed before proceeding to systemic treatment.
In patients with no prior systemic treatment (or only adjuvant treatment and recurrence after a long interval), the first-line approach is the carboplatin/paclitaxel + immunotherapy (dostarlimab or pembrolizumab) combination described above. Expected benefit is particularly high in the dMMR/MSI-H subgroup.
In pMMR patients progressing after first-line immunotherapy+chemotherapy, pembrolizumab+lenvatinib is a standard next-line option (Study 309 data above). Trastuzumab deruxtecan or trastuzumab+chemotherapy may be considered in HER2-positive serous carcinoma. Although initial immunotherapy responses in dMMR/MSI-H patients are often durable, options at progression are assessed similarly to other subgroups.
In disease progressing after multiple treatment lines, conventional salvage chemotherapy agents still have a role: doxorubicin or liposomal doxorubicin, docetaxel, and topotecan may provide disease control in selected patients, although response rates generally range from %4-27. Choice among these agents is individualized by response to previous treatments, accumulated toxicity (for example, cardiac reserve after previous anthracyclines), performance status and patient preference. Retrying platinum-based regimens is also an option in platinum-sensitive patients (recurring more than 6 months after the last platinum treatment); in platinum-resistant disease, the salvage agents above or referral to clinical trials, if appropriate, are recommended.
Side Effects of Treatment
| Treatment | Main Side Effects |
|---|---|
| Hysterectomy + salpingo-oophorectomy | Sudden postoperative menopause (if ovaries are removed), wound healing, rarely lymphedema (particularly after complete lymphadenectomy) |
| Radiotherapy | Short-term fatigue and urinary/bowel complaints; long-term vaginal dryness/narrowing, rarely urinary/fecal incontinence |
| Carboplatin + paclitaxel | Fatigue, nausea and vomiting, temporary hair loss, diarrhea, decreased blood counts, peripheral neuropathy |
| Dostarlimab / pembrolizumab (immunotherapy) | Immune-mediated side effects (such as thyroid dysfunction, colitis, pneumonia, skin rash) — mostly mild to moderate and manageable if recognized early |
| Lenvatinib | Hypertension, diarrhea, hand-foot syndrome, fatigue, proteinuria |
| Trastuzumab | Infusion reactions, rarely decreased cardiac function (requires cardiac monitoring) |
Global Approval and Evidence History
The Cancer Genome Atlas project demonstrated that uterine cancer divides into 4 distinct molecular subgroups (Nature) — laying the foundation for the field's future transformation.
TCGA's complex genomic classification was converted into a simplified test usable in routine pathology laboratories.
Showed similar diagnostic accuracy to routine complete lymphadenectomy and gradually began replacing the standard surgical approach.
The first immunotherapy combination approval in previously treated advanced disease that is not MSI-H/dMMR was granted based on Study 111/KEYNOTE-146.
León-Castillo A et al. showed that chemoradiotherapy benefit was largely concentrated in p53abn, while POLE-ultramutated patients had excellent outcomes regardless of treatment (J Clin Oncol).
Dostarlimab monotherapy received accelerated approval in dMMR/MSI-H patients progressing after chemotherapy (ORR %42,3) — the precursor to RUBY.
Converted to full FDA approval with confirmatory Study 309/KEYNOTE-775 data.
The updated European guideline recommended routine molecular classification for all patients and its direct guidance of adjuvant treatment decisions; percentage-based risk strata and molecular upgrading/downgrading rules were defined.
Dostarlimab+chemotherapy was approved first-line for the dMMR/MSI-H subgroup based on RUBY — the first step in moving immunotherapy into first-line treatment.
Powell MA et al. showed that carboplatin+paclitaxel was equivalent (even slightly superior) to ifosfamide+paclitaxel and less toxic — becoming the preferred regimen in carcinosarcoma.
Trastuzumab deruxtecan approval in HER2 IHC3+ solid tumors (including uterine cancer) — a %84,6 response rate was reported in the uterine cancer arm.
RUBY (dostarlimab+chemotherapy) expanded to full approval regardless of microsatellite status; NRG-GY018/KEYNOTE-868 (pembrolizumab+chemotherapy) also received approval close in time — immunotherapy is now a first-line option for all eligible patients.
Trastuzumab and trastuzumab deruxtecan entered guidelines for HER2-positive serous carcinoma, supported by randomized/single-arm phase data.
The Situation in Türkiye: TİTCK Licensing and SGK Reimbursement
Carboplatin and paclitaxel, the standard chemotherapy backbone, and megestrol acetate used in hormonal treatment are long-established generic drugs widely accessible under SGK coverage in Türkiye.
This research found no evidence that dostarlimab (Jemperli) is licensed by TİTCK or reimbursed by SGK in Türkiye. Instead, indirect findings suggest the drug is not widely accessible in Türkiye (such as a public petition launched for inclusion in SGK coverage). This suggests that this new drug based on RUBY is not routinely available in Türkiye as of August 2026 — patients are advised to confirm the current situation directly with their treatment centers.
Pembrolizumab (Keytruda) is reimbursed for lung, breast and head and neck cancers on the SGK list expanded in July 2025 — however, uterine (endometrial) cancer is absent from this list. According to documented legal sources, both first-line use (with carboplatin/paclitaxel) and the pembrolizumab+lenvatinib combination were rejected by TİTCK for "no license/insufficient data for this indication"; patients obtained court orders requiring SGK to pay (for example, litigation following a TİTCK rejection on March 3, 2025 and an İstanbul Commercial Court decision concluded on April 17, 2025). In the April 17, 2025 decision, the court-appointed expert panel explicitly found "pembrolizumab has no approval for uterine cancer" and "lenvatinib also has no approval for this use in our country" ; despite this, the court directed SGK to pay. In summary: access is possible, but only through individual litigation — it is not standard SGK coverage.
Trastuzumab is widely licensed and reimbursed in Türkiye for standard indications such as breast and stomach cancer. However, this research could not confirm a specific SGK reimbursement rule for its more recent, niche use in HER2-positive uterine (serous) cancer — the general pattern observed in other new indications (a licensed drug whose niche/new indication is not separately covered) suggests similar uncertainty for this use, but this is an inference, not a verified finding.
MSI/MMR immunohistochemistry and PCR tests are offered by multiple pathology laboratories in Türkiye and are clinically accessible. However, this research could not confirm whether POLE gene sequencing is routinely offered in Türkiye or whether SGK reimburses the full molecular classification panel (POLE+MMR+p53) as a package — a practical issue patients need to clarify with their treatment centers.
Uterine cancer repeats the pattern seen in many other cancers: decades-old generic drugs (carboplatin, paclitaxel, megestrol acetate) are readily accessible, while newer immunotherapy-based treatments developed after 2019 (dostarlimab, pembrolizumab, pembrolizumab+lenvatinib) appear unlicensed by TİTCK for this indication and are not covered by SGK; access is largely through individual litigation. This research found no litigation record specific to dostarlimab.
Frequently Asked Questions
- Why Is Uterine Cancer Incidence Rising?
- This increase is thought to be largely associated with the global rise in obesity prevalence — fat tissue contributes to extra estrogen production that stimulates the endometrium. Mortality rates are rising even faster than incidence, suggesting a disproportionate increase in aggressive subtypes.
- Should Everyone Have Molecular Classification Testing?
- Current (2023) European guidelines recommend routine testing in all uterine cancer patients — because the result can directly affect whether adjuvant treatment is intensified.
- Is Immunotherapy Now Used for All Patients?
- No, but its use has expanded greatly. Benefit is very pronounced in dMMR/MSI-H (approximately %25-30); in pMMR/MSS, there is a more modest but real benefit. Eligibility is determined by MMR/MSI testing on tumor tissue.
- I Want to Preserve My Fertility. Is This Possible?
- For selected young patients with early-stage, low-grade (grade 1) endometrioid cancer, a fertility-preserving approach using progestin-based hormonal treatment instead of surgery may be considered. This is a special situation requiring close monitoring by an experienced gynecological oncology team.
- I Had Light Spotting After Menopause. Should I Be Concerned?
- Any postmenopausal bleeding or spotting, however small the amount, must be assessed by a gynecologist. Although often due to a noncancerous cause, this is the earliest and most reliable warning sign of uterine cancer.
- Is Carcinosarcoma Treated Differently from Other Uterine Cancers?
- Yes. Carcinosarcoma is a distinct, aggressive subtype with both carcinoma and sarcoma components. Although ifosfamide-based regimens were historically used, GOG-261 showed that carboplatin+paclitaxel has become the preferred standard with equivalent (even slightly better) efficacy and significantly less toxicity.
- What Treatment Is Used if the Disease Recurs?
- There is no single answer; the decision depends on multiple factors: whether recurrence is local or distant, prior radiotherapy/immunotherapy, MMR/HER2 status and platinum sensitivity. Local recurrence alone may sometimes achieve lasting control with salvage radiotherapy, while in systemic recurrence, immunotherapy combinations, pembrolizumab+lenvatinib, HER2-targeted agents or, at later lines, conventional salvage agents such as doxorubicin/docetaxel/topotecan are assessed sequentially.
- Sung H, et al. Global cancer statistics 2024. CA Cancer J Clin. 2026. DOI: 10.3322/caac.70090.
- Siegel RL, et al. Cancer Statistics, 2026. CA Cancer J Clin. 2026. DOI: 10.3322/caac.70043.
- The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013. DOI: 10.1038/nature12113.
- Talhouk A, et al. ProMisE molecular classifier. Br J Cancer. 2015 and subsequent validation studies.
- Concin N, et al. ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma. Int J Gynecol Cancer. 2023.
- Rossi EC, et al. FIRES study (sentinel lymph node mapping). Lancet Oncol. 2017.
- Creutzberg CL, et al. PORTEC-1 study: The role of adjuvant radiotherapy. Lancet. 2000.
- Nout RA, et al. PORTEC-2 study: Comparison of vaginal brachytherapy and external radiotherapy. Lancet. 2010; Wortman BG, et al. 10-year long-term follow-up. Br J Cancer. 2018.
- de Boer SM, et al. PORTEC-3 study: Chemoradiotherapy vs radiotherapy. Lancet Oncol. 2018-2019.
- León-Castillo A, et al. PORTEC-3 molecular subgroup analysis. J Clin Oncol. 2020.
- Matei D, et al. GOG-258/NRG258 study: Chemoradiotherapy vs chemotherapy, advanced-stage disease. N Engl J Med. 2019 (long-term follow-up 2024-2025).
- Powell MA, et al. GOG-261 study: Carboplatin+paclitaxel vs ifosfamide+paclitaxel in carcinosarcoma. J Clin Oncol. 2022.
- FDA. Dostarlimab (GARNET study) monotherapy accelerated approval, April 22, 2021.
- Makker V, et al. Study 309/KEYNOTE-775: Lenvatinib+pembrolizumab. N Engl J Med. 2022.
- Mirza MR, et al. RUBY study: Dostarlimab+chemotherapy. N Engl J Med. 2023.
- Eskander RN, et al. NRG-GY018/KEYNOTE-868: Pembrolizumab+chemotherapy. N Engl J Med. 2023.
- FDA. RUBY and NRG-GY018/KEYNOTE-868 all-comer first-line approvals, August 1, 2024.
- Fader AN, et al. Phase 2 study of trastuzumab in HER2-positive serous carcinoma and updated overall survival analysis. J Clin Oncol. 2018 and updates.
- Meric-Bernstam F, et al. DESTINY-PanTumor02 study: Trastuzumab deruxtecan. J Clin Oncol. 2023 (PMID: 37870536); FDA tumor-agnostic approval, April 5, 2024.
- Turkish Cancer Society. Drugs added to SGK's reimbursement list in July 2025.
- Relevant articles of Türkiye's Health Implementation Communiqué (SUT), TİTCK drug license lists.
Was this article helpful?
Your feedback helps us improve our content.
